Key Drivers
- Strong liquidity
- Persistent losses
- High R&D spend
AIAI Summary
IDEAYA has shifted from a pure burn story into a near‑term, cash‑backed, binary investment where a >$1B runway into 2030 plus imminent darovasertib topline and Phase‑3 progressions make clinical readouts and disciplined burn management the primary drivers of upside or dilution. If darovasertib and at least one mid‑late program deliver regulatorily persuasive data while management preserves runway, valuation upside is credible; disappointing readouts or materially higher burn that shortens runway would sharply increase dilution risk and devalue the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Persistent losses
- •High R&D spend
IDYA has strong liquidity and negligible financial leverage but is materially unprofitable with persistent operating and free‑cash‑flow losses driven by very high R&D and operating spend that erode returns.
Price Behavior
Key Price Behavior Insights:
- •Recent pullback
- •Support-tested
- •Volatile intraday moves
Modest net gain over the last month but recent pullback leaves the stock below its short-term average—reclaiming the mid-$35s would confirm a short-term rebound, while failure of the $31.6–$32.1 support risks a deeper decline.
Several sharp daily moves up and down over the period indicate unstable short-term volatility
Sentiment & News
Key News Insights:
- •Dual first‑patient‑in
- •AACR data plan
- •Leadership hires
IDEAYA reports near‑term clinical advancement with first‑patient‑in for IDE034 and IDE892, AACR poster disclosures, recent C‑suite hires and equity grants, and a strategic shift toward proprietary MTAP‑deleted/CDKN2A programs.
These developments should increase near‑term clinical visibility and could positively re‑rate the stock if forthcoming data and readouts validate program progress
Similar Companies in Healthcare
Other companies in the same sector with AI ratings